Kiribati vs Marshall Islands: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Kiribati
0.9%
in 2024
Marshall Islands
0.9%
in 2024
Kiribati rank
35th
Marshall Islands rank
35th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Kiribati
- Marshall Islands
How they compare
Kiribati currently reports 0.9% against 0.9% in Marshall Islands, a difference of 0.0%.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Kiribati ahead.
Kiribati ranks 35th and Marshall Islands ranks 35th of 215 countries.
Kiribati has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Kiribati | Marshall Islands | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.9% | 1.4% | 0.5% | Kiribati |
| 2020s | 1.1% | 1.0% | 0.1% | Kiribati |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Kiribati or Marshall Islands?
- Kiribati, at 0.9% against 0.9% in Marshall Islands as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Kiribati and Marshall Islands?
- 0.0%, with Kiribati ahead.
- How many years of comparable data are there for Kiribati and Marshall Islands?
- 10 years are reported by both, from 2015 to 2024.
- How do Kiribati and Marshall Islands rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Kiribati ranks 35th and Marshall Islands ranks 35th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.